Drug Trial Radar · NCT01702428
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,016
Actual
Start
Nov 9, 2012
Primary completion
Nov 25, 2014
Study completion Apr 16, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 8, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Conditions
- Rubella
- Measles
- Mumps
Interventions
PriorixBiological
Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
M-M-R IIBiological
Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
VarivaxBiological
Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
HavrixBiological
Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
Prevnar 13Biological
US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-valueTime frame: At Day 42
- Anti-measles Virus Antibody ConcentrationsTime frame: At Day 42
- Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-valueTime frame: At Day 42
- Anti-mumps Virus Antibody ConcentrationTime frame: At Day 42
- Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-valueTime frame: At Day 42
- Anti-rubella Virus Antibody ConcentrationTime frame: At Day 42
- Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR GroupsTime frame: At Day 42
- Anti-measles Virus Antibody Concentrations in Pooled MMR GroupsTime frame: At Day 42
- Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR GroupsTime frame: At Day 42
- Anti-mumps Virus Antibody Concentration in Pooled MMR GroupsTime frame: At Day 42
- Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR GroupsTime frame: At Day 42
- Anti-rubella Virus Antibody Concentration in Pooled MMR GroupsTime frame: At Day 42
Locations
90 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Dothan, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Daly City, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Hayward, California
GSK Investigational Site
Los Gatos, California
GSK Investigational Site
Mission Hills, California
GSK Investigational Site
Paramount, California
GSK Investigational Site
Pleasanton, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Santa Clara, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Evergreen Park, Illinois
GSK Investigational Site
Ames, Iowa
GSK Investigational Site
Augusta, Kansas
GSK Investigational Site
Overland Park, Kansas
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Bossier City, Louisiana
GSK Investigational Site
Columbia, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Niles, Michigan
GSK Investigational Site
Stevensville, Michigan
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Ithaca, New York
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Erie, Pennsylvania
GSK Investigational Site
Hermitage, Pennsylvania
GSK Investigational Site
Sellersville, Pennsylvania
GSK Investigational Site
Warwick, Rhode Island
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.